Ultragenyx Pharmaceutical RARE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's net change in cash?
- Ultragenyx Pharmaceutical (RARE) reported net change in cash of -$247M in Q1 2026.
- How has Ultragenyx Pharmaceutical's net change in cash changed year-over-year?
- Ultragenyx Pharmaceutical's net change in cash decreased by 448.9% year-over-year, from -$45M to -$247M.
- What is the long-term trend for Ultragenyx Pharmaceutical's net change in cash?
- Over 2 years (2022 to 2025), Ultragenyx Pharmaceutical's net change in cash has grown at a 18.8% compound annual growth rate (CAGR), from -$178.49M to $252M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.